Abingworth’s Protara Therapeutics TARA Stock Holding History

Abingworth’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,610	Closed	-$344K	–	18
2020 Q3	$344K	Sell	20,610 -33,002	-62%	-$765K	0.07%	15
2020 Q2	$3M	Sell	53,612 -60,307	-53%	-$1.87M	0.84%	11
2020 Q1	$2.62M	Buy	113,919 +60,306	+112%	+$1.76M	1.74%	11
2019 Q4	$879K	Buy	53,613 +3,166	+6%	+$36.3K	0.42%	12
2019 Q3	$525K	Hold	50,447	–	–	0.33%	12
2019 Q2	$851K	Hold	50,447	–	–	0.33%	12
2019 Q1	$1.01M	Hold	50,447	–	–	0.9%	12
2018 Q4	$4.58M	Hold	50,447	–	–	4.16%	8
2018 Q3	$3.83M	Hold	50,447	–	–	2.28%	7
2018 Q2	$4.84M	Hold	50,447	–	–	2.77%	6
2018 Q1	$5.04M	Hold	50,447	–	–	3.14%	6
2017 Q4	$3.73M	Hold	50,447	–	–	2.7%	7
2017 Q3	$3.94M	Hold	50,447	–	–	2.72%	6
2017 Q2	$3.03M	Hold	50,447	–	–	2.41%	7
2017 Q1	$3.43M	Hold	50,447	–	–	2.56%	7
2016 Q4	$3.63M	Hold	50,447	–	–	3.04%	6
2016 Q3	$18.4M	Hold	50,447	–	–	17.62%	2
2016 Q2	$16.3M	Hold	50,447	–	–	17.03%	2
2016 Q1	$15.6M	Hold	50,447	–	–	14.46%	3
2015 Q4	$31.3M	Hold	50,447	–	–	18.88%	2
2015 Q3	$27.4M	Hold	50,447	–	–	16.02%	2
2015 Q2	$36M	Hold	50,447	–	–	16.36%	2
2015 Q1	$22.7M	Hold	50,447	–	–	9.64%	5
2014 Q4	$20.3M	Buy	+50,447	New	+$20.3M	5.78%	7

Other funds holding TARA

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Abingworth's TARA Position: Q4 2020 in Review

Abingworth sold out of Protara Therapeutics (TARA) in Q4 2020, closing a stake of 20,610 shares — an estimated $344K sold.

Abingworth first reported a position in TARA in Q4 2014 and held it in 24 quarters. The position peaked at $36M in Q2 2015. 49 funds tracked by Wall St. Rank hold TARA as of Q4 2020.

Abingworth reported no remaining Protara Therapeutics position as of Q4 2020 after selling out during the quarter.
Abingworth sold 20,610 Protara Therapeutics shares in Q4 2020, an estimated $344K.
Abingworth first reported a position in Protara Therapeutics in Q4 2014 and held it in 24 quarters.
Abingworth's Protara Therapeutics position peaked at $36M in Q2 2015.
49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2020.

Based on Abingworth's 13F filing for Q4 2020, filed 1 Mar 2021.